Skip to main content
All lobbying clients

TRAVERE THERAPEUTICS

Lobbying client · California · filed 2025 to 2026

Prescription pharmaceutical manufacturer of medications.

$1,828,000 Reported spend
25 Filings counted
4 Outside firms hired
14 Bills named

Spend is reported income plus in-house expenses across 25 filings. 2 further filings for this client were restated by a later amendment and are left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 5 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as TRAVERE THERAPEUTICS, INC.

 Who filed for this client 5

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 14
  • H.R. 1518
    New Era of Preventing End-Stage Kidney Disease Act
    15 filings
  • H.R. 1414
    Cameron’s Law
    14 filings
  • H.R. 946
    ORPHAN Cures Act
    14 filings
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    10 filings
  • S. 1040
    A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Vete…
    7 filings
  • H.R. 1
    One Big Beautiful Bill Act
    7 filings
  • S. 1862
    ORPHAN Cures Act
    6 filings
  • H.R. 4709
    Newborn Screening Saves Lives Reauthorization Act of 2025
    5 filings
  • S. 932
    Give Kids a Chance Act of 2025
    3 filings
  • H.R. 10571
    Surge to Save Newborns Act
    2 filings
  • H.R. 9102
    BINSA Act
    2 filings
  • S. 2658
    Medication Affordability and Patent Integrity Act
    2 filings
  • H.R. 10359
    Priority for Pediatric Cures Act
    1 filing
  • H.R. 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
    1 filing
 Reported by year 2 years
  • 2026 $702,000 9 filings
  • 2025 $1,126,000 16 filings
 Issues lobbied 7

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 4
  • HOUSE OF REPRESENTATIVES 21
  • SENATE 16
  • Centers For Medicare and Medicaid Services (CMS) 7
  • Health & Human Services, Dept of (HHS) 7
 Recent filings 27 total
Q3 report
ALSTON & BIRD LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View →
Q3 report
TRAVERE THERAPEUTICS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $100,000 expenses · posted Oct 19, 2026
View →
Q2 report
THE HEALTH EQUITY STRATEGIES GROUP, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $16,000 income · posted Aug 4, 2026
View →
Q2 report
ALSTON & BIRD LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $70,000 income · posted Jul 20, 2026
View →
Q2 report
TRAVERE THERAPEUTICS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $140,000 expenses · posted Jul 20, 2026
View →
Q1 report
THE HEALTH EQUITY STRATEGIES GROUP, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · $16,000 income · posted May 19, 2026
View →
Q1 report
ALSTON & BIRD LLP
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 20, 2026
View →
Q1 report
TRAVERE THERAPEUTICS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $200,000 expenses · posted Apr 20, 2026
View →
Q1 terminationNo activity
LMH STRATEGIC SOLUTIONS
1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 17, 2026
View →
Q1 report
LMH STRATEGIC SOLUTIONS Amended
1st Quarter 2026 (Jan 1 - Mar 31) · $30,000 income · posted Apr 17, 2026
View →
Q1 amendment
ALSTON & BIRD LLP
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Mar 3, 2026
View →
Q4 report
THE HEALTH EQUITY STRATEGIES GROUP, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · $16,000 income · posted Feb 20, 2026
View →
Q4 report
ALSTON & BIRD LLP
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $80,000 income · posted Jan 20, 2026
View →
Q4 report
TRAVERE THERAPEUTICS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $260,000 expenses · posted Jan 19, 2026
View →
Q4 report
LMH STRATEGIC SOLUTIONS
4th Quarter 2025 (Oct 1 - Dec 31) · $30,000 income · posted Jan 12, 2026
View →
Q3 report
THE HEALTH EQUITY STRATEGIES GROUP, LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · $16,000 income · posted Nov 20, 2025
View →
Q3 report
ALSTON & BIRD LLP
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $70,000 income · posted Oct 20, 2025
View →
Q3 report
LMH STRATEGIC SOLUTIONS
3rd Quarter 2025 (July 1 - Sep 30) · $20,000 income · posted Oct 20, 2025
View →
Q3 report
TRAVERE THERAPEUTICS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $110,000 expenses · posted Oct 16, 2025
View →
Registration
LMH STRATEGIC SOLUTIONS
3rd Quarter 2025 (July 1 - Sep 30) · posted Aug 28, 2025
View →

Showing the 20 most recent of 27 filings. Search the explorer for "TRAVERE THERAPEUTICS".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem